Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

      Date of report (Date of earliest event reported): September 16, 2002

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

           Delaware                      000-14879               222322400
 (State or Other Jurisdiction    (Commission File Number)      (IRS Employer
       of Incorporation)                                     Identification No.)

650 College Road East, CN 5308, Suite 3100, Princeton, NJ              08540
(Address of Principal Executive Offices)                             (Zip Code)

                                 (609) 750-8200
              (Registrant's telephone number, including area code)

               600 College Road East, CN 5308, Princeton, NJ 08540
          (Former Name or Former Address, if Changed Since Last Report)

         Item 5.           Other Events.

     On September 16, 2002,  Cytogen  Corporation (the "Company") issued a press
release reporting the internal restructuring of the Company's AxCell Biosciences

     On  September  17,  2002,  the Company  issued a joint press  release  with
Matritech  Inc.  announcing  an agreement in principle to enter into a five year
agreement  for  the  Company  to be  the  sole  United  States  distributor  for
Matritech's  NMP22(R)  BladderChek(TM)  test.  Such  arrangement  is pending the
approval and execution of a final agreement by both parties.

     Each such press  release is  attached  hereto as Exhibit  99.1 and  Exhibit
99.2, respectively,  and each is incorporated herein by reference. The foregoing
description of each such press release is qualified in its entirety by reference
to each such respective document.

         Item 7.  Financial Statements, Pro Forma Financial Information
and Exhibits.

         (c) Exhibits.

          Exhibit No.      Description
          -----------      -----------
             99.1          Press release of the Company dated September 16, 2002
             99.2          Press release of the Company dated September 17, 2002


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                         Cytogen Corporation

                                         By: /s/ Lawrence R. Hoffman
                                              Lawrence R. Hoffman,
                                               Chief Financial Officer

Date:  September 17, 2002